---
title: "Allogene Therapeutics | 8-K: FY2026 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304535194.md"
datetime: "2026-11-05T22:13:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304535194.md)
  - [en](https://longbridge.com/en/news/304535194.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304535194.md)
generator: "portal-rs"
---

# Allogene Therapeutics | 8-K: FY2026 Q3 Revenue: USD 0

Revenue: As of FY2026 Q3, the actual value is USD 0.

EPS: As of FY2026 Q3, the actual value is USD -0.15, compared to the market estimate of USD -0.1471.

EBIT: As of FY2026 Q3, the actual value is USD -49.91 M.

### Financial Results for the Three Months Ended September 30, 2026, and 2025

#### Operating Expenses

-   Research and development expenses were $41,934 thousand for Q3 2026, compared to $31,164 thousand for Q3 2025. This included $2.9 million of non-cash stock-based compensation expense for Q3 2026.
-   General and administrative expenses were $12,859 thousand for Q3 2026, compared to $13,737 thousand for Q3 2025. This included $4.2 million of non-cash stock-based compensation expense for Q3 2026.
-   Total operating expenses were $54,793 thousand for Q3 2026, compared to $44,901 thousand for Q3 2025.

#### Profitability

-   Loss from operations was - $54,793 thousand for Q3 2026, compared to - $44,901 thousand for Q3 2025.
-   Net loss was - $50,369 thousand for Q3 2026, compared to - $41,400 thousand for Q3 2025. This figure included total non-cash stock-based compensation expense of $7.0 million for Q3 2026.

#### Other Income/Expenses

-   Net interest and other income was $4,879 thousand for Q3 2026, compared to $3,926 thousand for Q3 2025.
-   Interest expense was - $379 thousand for Q3 2026, compared to - $344 thousand for Q3 2025.
-   Other income (expenses), net, was - $76 thousand for Q3 2026, compared to - $81 thousand for Q3 2025.
-   Total other income (expenses), net, was $4,424 thousand for Q3 2026, compared to $3,501 thousand for Q3 2025.

### Selected Balance Sheet Data

#### Cash and Investments

-   Cash, cash equivalents and investments totaled $388,873 thousand as of September 30, 2026, compared to $258,253 thousand as of December 31, 2025.

#### Assets and Liabilities

-   Total assets were $511,320 thousand as of September 30, 2026, compared to $415,905 thousand as of December 31, 2025.
-   Total liabilities were $118,768 thousand as of September 30, 2026, compared to $123,363 thousand as of December 31, 2025.
-   Total stockholders’ equity was $392,552 thousand as of September 30, 2026, compared to $292,542 thousand as of December 31, 2025.

### Outlook / Guidance

Allogene Therapeutics, Inc. expects its next ALPHA3 clinical update in mid-2027, with trial enrollment anticipated to conclude by year-end 2027. The company projects its cash runway will extend into 2029. Total operating expenses for 2026 are estimated to be approximately $165 million, with GAAP Operating Expenses at $225 million, including about $35 million in non-cash stock-based compensation.

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)

## Related News & Research

- [Allogene's ALLO-329 improves skin scores in 8 of 10 scleroderma patients in Phase 1 trial](https://longbridge.com/en/news/304856012.md)
- [ALLO: ALLO-329 showed early SSc activity across LD approaches, including no lymphodepletion](https://longbridge.com/en/news/304856871.md)
- [Allogene Therapeutics (ALLO) Expected to Release Earnings on Thursday](https://longbridge.com/en/news/303544335.md)
- [Allogene Therapeutics Plans to Attend Three Investor Conferences](https://longbridge.com/en/news/303083684.md)
- [Allogene Highlights CAR T Clinical Progress in Kidney Cancer at SITC Meeting](https://longbridge.com/en/news/304117819.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**